ReviewCNS oncology2021
Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.
Review in CNS oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience.Advanced healthcare materials · 2026Pooled it
- Improvement in visual outcomes of patients with base of skull meningioma as a result of evolution in the treatment techniques in the last three decades: a systematic review.Journal of neuro-oncology · 2023Pooled it
- A Machine Learning Model Based on Unsupervised Clustering Multihabitat to Predict the Pathological Grading of Meningiomas.BioMed research international · 2022Trial
- Geographic Trends and Disparities in Meningioma Mortality: A National Observational Study from 1999 to 2020 Utilizing the CDC Wonder Database.Journal of neurological surgery. Part B, Skull base · 2026Article
- Pan-TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity.The journal of pathology. Clinical research · 2026Article
- MIB-1 index predicts low recurrence risk after subtotal resection of meningiomas: a retrospective study of 505 patients.Neurosurgical review · 2026Article
- Multimodal MRI-based nomogram integrating clinical-radiological, radiomic, and habitat features to discriminate solitary fibrous tumors from atypical meningiomas.Scientific reports · 2026Article
- Lactobacillus-derived indole-3-lactic acid suppresses meningioma malignant phenotypes by direct anti-proliferative effects and macrophage reprogramming.Journal of translational medicine · 2026Article
- Survival Outcomes and Prognostic Factors in Patients with Meningioma: A Single-Center Study at the Indonesian National Cancer Center Dharmais Hospital (2019-2025).Current oncology (Toronto, Ont.) · 2026Article
- The meninges as a neuroimmune interface: structure, barriers and roles in CNS disease.Fluids and barriers of the CNS · 2026Review
- Team-Based Long-Term Multidisciplinary Inpatient Neurological Rehabilitation After Surgery of Cerebral Meningioma-Outcome and Confounding Factors.Brain sciences · 2026Article
- The public health burden of nervous system tumors in Anambra State, Nigeria necessitates strategic resource allocation.Scientific reports · 2026Article
- Mebendazole Attenuates Cellular Invasion in a 3D Culture Model of Meningioma by Disrupting Rho-GTPase-Mediated Microtubule Function.Oncology research · 2026Article
- A rare combination of a meningioma and an ethmoidal meningoencephalocele with osteo-dural defect: Diagnostic and therapeutic challenges.Surgical neurology international · 2026Article
- Olfactory groove meningioma presenting solely with visual impairment: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Brain neurovascular unit in response to intra- and extra-central nervous system cancers: implications, mechanisms, and challenges.Cancer cell international · 2025Review
- Novel predictors of tumor growth by exploratory quantitative analysis of radiomics features from MRI data for incidentally discovered meningioma.Journal of neuro-oncology · 2025Article
- GABA treatment promoting cell apoptosis in meningioma correlates with EGFR/BCL-2/BAX axis.Journal of neuro-oncology · 2025Article
- Extracranial Extension of a Convexity Meningioma into the Temporal Fossa: A Rare Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Identification of SLC7A1 as a potential therapeutic target for high-grade meningioma.Cell death discovery · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are the most common primary intracranial tumors. The majority of meningiomas are benign, but they can present different grades of dedifferentiation from grade I to grade III (anaplastic/malignant) that are associated with different outcomes. Radiological surveillance is a valid option for low-grade asymptomatic meningiomas. In other cases, the treatment is usually surgical, aimed at achieving a complete resection. The use of adjuvant radiotherapy is the gold standard for grade III, is debated for grade II and is not generally indicated for radically resected grade I meningiomas. The use of systemic treatments is not standardized. Here we report a review of the literature on the clinical, radiological and molecular characteristics of meningiomas, available treatment strategies and ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.